Reduced expression of sushi domain containing 2 is associated with progression of non-small cell lung cancer

被引:9
|
作者
Cai, Cuixia [1 ]
Shi, Rong [1 ]
Gao, Yuan [1 ]
Zeng, Jun [1 ]
Wei, Min [1 ]
Wang, Handuo [1 ]
Zheng, Wenling [1 ]
Ma, Wenli [1 ]
机构
[1] Southern Med Univ, Inst Genet Engn, Guangzhou 510515, Guangdong, Peoples R China
关键词
sushi domain containing 2; non-small cell lung cancer; tissue microarray; immunohistochemistry; ADENOCARCINOMA; EPIDEMIOLOGY; APOPTOSIS; GENE; PCR;
D O I
10.3892/ol.2015.3737
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sushi domain containing 2 (SUSD2) has been identified as a gene encoding an 822-amino acid protein, which contains a transmembrane domain and functional domains inherent to adhesion molecules. Previous studies have reported that increased expression of SUSD2 has a critical role in tumorigenesis in human breast cancer. However, to the best of our knowledge, SUSD2 expression status and its correlation with the clinicopathological features of non-small cell lung cancer (NSCLC) have not previously been investigated. In the present study, reverse transcription-quantitative polymerase chain reaction and western blotting were used to evaluate SUSD2 messenger RNA (mRNA) and protein expression in NSCLC and adjacent normal lung tissues. The clinicopathological significance of SUSD2 was investigated by immunohistochemical analysis of an NSCLC tissue microarray. Receiver operating characteristic analysis was used to determine the cut-off score for positive expression of SUSD2. Furthermore, the correlation between SUSD2 expression and the clinicopathological features of NSCLC was analyzed by (2) test. The results revealed that SUSD2 mRNA (P<0.0001) and protein (P<0.0001) expression levels were significantly decreased in NSCLC tissues compared with those of adjacent normal tissues. When the SUSD2 positive expression percentage was determined to be >47.5% (area under ROC curve, 0.799; P<0.000), positive expression of SUSD2 was observed in 100% (32/32) of normal lung tissues and 55% (88/160) of NSCLC tissues by immunohistochemistry ((2)=21.160; P<0.000). Furthermore, it was demonstrated that the reduced SUSD2 protein levels in cancer tissues were positively correlated with poor histological grade ((2)=41.764; P<0.000), advanced clinical stage ((2)=10.790; P=0.013), higher pT ((2)=9.070; P=0.028) and positive regional lymph node metastasis ((2)=15.399; P=0.002). In conclusion, these data suggest that the reduced expression of SUSD2 is associated with the progression of NSCLC and may have a role in the pathogenesis of NSCLC.
引用
收藏
页码:3619 / 3624
页数:6
相关论文
共 50 条
  • [1] Expression profiles associated with disease progression in non-small cell lung cancer
    Frankenberger, C.
    Basu, S.
    Bild, N.
    Potti, A.
    Raponi, M.
    Wang, Y.
    Beer, D. G.
    Coon, J.
    Bonomi, P.
    Borgia, J. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Abnormal β-catenin and reduced axin expression are associated with poor differentiation and progression in non-small cell lung cancer
    Xu, HT
    Wang, L
    Lin, D
    Liu, Y
    Liu, N
    Yuan, XM
    Wang, EH
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 125 (04) : 534 - 541
  • [3] WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer
    Yendamuri, S
    Kuroki, T
    Trapasso, F
    Henry, AC
    Dumon, KR
    Huebner, K
    Williams, NN
    Kaiser, LR
    Croce, CM
    [J]. CANCER RESEARCH, 2003, 63 (04) : 878 - 881
  • [4] Elevated thymosin β15 expression is associated with progression and metastasis of non-small cell lung cancer
    Gu, Yu-Mei
    Li, Shu-Yu
    Qiu, Xue-Shan
    Wang, En-Hua
    [J]. APMIS, 2008, 116 (06) : 484 - 490
  • [5] Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer
    Noh, Sang Jae
    Baek, Hyun Ah
    Park, Ho Sung
    Jang, Kyu Yun
    Moon, Woo Sung
    Kang, Myoung Jae
    Lee, Dong Geun
    Kim, Min Ho
    Lee, Ju Hyung
    Chung, Myoung Ja
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2013, 209 (06) : 365 - 370
  • [6] Metastatic non-small cell lung cancer: Costs associated with disease progression
    Fox, Kathleen M.
    Brooks, John M.
    Kim, Jennifer
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2008, 14 (09): : 565 - 571
  • [7] Reduced expression of claudin-7 is associated with poor outcome in non-small cell lung cancer
    Yamamoto, Taketsugu
    Oshima, Takashi
    Yoshihara, Kazue
    Yamanaka, Sumitaka
    Nishii, Teppei
    Arai, Hiromasa
    Inui, Kenji
    Kaneko, Takeshi
    Nozawa, Akinori
    Woo, Tetsukan
    Rino, Yasushi
    Masuda, Munetaka
    Imada, Toshio
    [J]. ONCOLOGY LETTERS, 2010, 1 (03) : 501 - 505
  • [8] Bmi-1 expression modulates non-small cell lung cancer progression
    Xiong, Dan
    Ye, Yunlin
    Fu, Yujie
    Wang, Jinglong
    Kuang, Bohua
    Wang, Hongbo
    Wang, Xiumin
    Zu, Lidong
    Xiao, Gang
    Hao, Mingang
    Wang, Jianhua
    [J]. CANCER BIOLOGY & THERAPY, 2015, 16 (05) : 756 - 763
  • [9] SUMO-1 expression modulates non-small cell lung cancer progression
    Ke, Changkang
    Zhu, Kai
    Sun, Ying
    Zhang, Zhipei
    Ni, Yunfeng
    Li, Xiaofei
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (06): : 6054 - +
  • [10] Integrin alpha 2 is associated with tumor progression and postoperative recurrence in non-small cell lung cancer
    Matsumoto, Yoko
    Kage, Hidenori
    Morota, Mizuki
    Zokumasu, Koichi
    Ando, Takahiro
    Maemura, Keita
    Watanabe, Kousuke
    Kawakami, Masanori
    Hinata, Munetoshi
    Ushiku, Tetsuo
    Nakajima, Jun
    Nagase, Takahide
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (01) : 63 - 73